PAHC — PHIBRO ANIMAL HEALTH CORP
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1069899 ·
Last close
$37.40
Market Cap
$789.35M
52W High
$59.64
52W Low
$28.04
ADV30
255,898
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 396,747,000 | 134,401,000 | 48,157,000 | 21,710,000 | 1,501,241,000 | 61,419,000 | 1,115,764,000 |
| Mar 2026 | 383,543,000 | 125,675,000 | 44,653,000 | 24,024,000 | 1,445,118,000 | 54,929,000 | 1,083,291,000 |
| Dec 2025 | 373,910,000 | 132,656,000 | 50,326,000 | 27,459,000 | 1,405,553,000 | 55,486,000 | 1,073,192,000 |
| Sep 2025 | 363,893,000 | 119,783,000 | 51,260,000 | 26,527,000 | 1,385,524,000 | 72,769,000 | 1,073,843,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$66,132,000
Investing CF
$-62,038,000
Financing CF
$-12,711,000
CapEx
$-53,361,000
Dividends Paid
$-19,460,000
Buybacks
—
EPS Diluted TTM
$2.33
As of
2026-08-30
Balance + Analyst (yfinance extras)
Retained Earnings
$336,115,000
Inventory
$539,699,000
Receivables
$221,546,000
ST Investments
$22,522,000
EBIT TTM
$171,232,000
Pretax Income TTM
$128,852,000
Interest Exp TTM
$42,380,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,518,093,056
EBITDA
$244,231,008
Free Cash Flow
$-19,298,000
Enterprise Value
$2,157,894,144
Total Cash
$83,983,000
Total Debt
$795,648,000
Shares Out
21,105,569
Trailing EPS
$2.43
Book Value
$9.50
ROE
29.7%
ROA
8.5%
Div Yield
1.35%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,518,093,000 | 194,396,000 | 99,720,000 | 1,501,241,000 | 1,115,764,000 | 385,477,000 | 68,954,000 |
| Jun 2025 | 1,296,215,000 | 110,465,000 | 48,264,000 | 1,360,900,000 | 1,075,218,000 | 285,682,000 | 80,124,000 |
| Jun 2024 | 1,017,679,000 | 53,315,000 | 2,416,000 | 982,184,000 | 725,543,000 | 256,641,000 | 87,594,000 |
| Jun 2023 | 977,889,000 | 71,847,000 | 32,606,000 | 971,397,000 | 688,888,000 | 282,509,000 | 13,310,000 |
TTM Snapshot
Revenues TTM
$1,500,043,000
NetIncome TTM
$95,234,000
OpCashFlow TTM
—
Assets (Latest)
$1,445,118,000
Forward EPS
$3.85
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $37.40 · call volume: 74 · put volume: 67
Expected Move to 2026-12-18:
±$9.00
(24.06%) —
implied range
$28.40 –
$46.40
· ATM straddle on $35.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IVA | Inventiva S.A. | $784.25M | $3.32 | — |
| GERN | GERON CORP | $783.82M | $1.22 | — |
| HELP | Helus Pharma Inc. | $783.21M | $10.72 | — |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $783.12M | $1.76 | — |
| IVEVF | Inventiva S.A. | $760.63M | $3.22 | — |
News headlines (Yahoo Finance, 1h cache)
Is it the Right Time to Add Phibro Stock to Your Portfolio?
2026-10-08 16:22 · Yahoo
PAHC vs. HAE: Which Stock Is the Better Value Option?
2026-10-05 14:40 · Yahoo
Why Is Phibro (PAHC) Down 6.7% Since Last Earnings Report?
2026-09-25 14:30 · Yahoo
Phibro Animal Health (PAHC): Buy, Sell, or Hold Post Q2 Earnings?
2026-09-24 15:36 · Yahoo
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
2026-09-18 15:40 · Yahoo
Does Phibro (PAHC) Have the Potential to Rally 25.77% as Wall Street Analysts Expect?
2026-09-14 13:55 · Yahoo
Teladoc Strengthens Solo Platform With New AI-Powered Care Tools
2026-10-08 14:47 · Yahoo
Encompass Health Expands Rehab Footprint With New Maine Hospital
2026-10-07 15:08 · Yahoo
Is This the Right Time to Add TMO Stock to Your Portfolio?
2026-10-07 12:45 · Yahoo
Neogen Stock Rallies 83% YTD: What's Driving the Surge?
2026-10-01 11:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.